SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Fannie Lou Hamer

PatientFannie Lou Hamer
Date of birth1976-10-06
IdentifiersMRN HR-ML031-SYN; SSN (made up) 000-31-2479
Document date2026-07-13
AuthorLorraine Batiste-Hill, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose. [S]

History of Present Illness

Mrs. Hamer returns two months after her last review, brought by the health center's van as booked. Her home readings averaged 131/82 at the four-week phone check and 127/79 since, so no dose change was needed. She has had no low blood sugar, dizziness, cough or genital itching. She has finished the diabetes classes. The energy assistance was approved, and with SNAP and the produce program the food lasts through the month. She walks most days, though her legs ache. Her mood is steady. [S]

ElementDetail
Home blood pressureAverage 127/79
Diabetes classesCompleted
BenefitsSNAP and energy assistance in place
MoodPHQ-9 3

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo dizziness; weight down 2 kg
CardiovascularNegativeNo ankle swelling
GenitourinaryNegativeNo burning or genital itching
MusculoskeletalPositiveLeg aching after walking
PsychiatricNegativeMood steady

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening mealTwo tablets with the evening meal (after one week of one tablet)Oral route2026-03-09 to 2026-07-13completedS
Metformin extended-release 500 mg oral tablet, three tablets with the evening mealThree tablets with the evening mealOral route2026-07-13activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-09activeS
Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule dailyOne capsule dailyOral route2026-03-23activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet daily, with sick-day rulesOral route2026-03-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-13Body height163cmS
2026-07-13Body weight90.9kgS
2026-07-13Body mass index (BMI) [Ratio]34.2kg/m2S
2026-07-13Systolic blood pressure128mm[Hg]S
2026-07-13Diastolic blood pressure78mm[Hg]S
2026-07-13Heart rate76/minS
2026-07-13Respiratory rate16/minS
2026-07-13Body temperature36.9CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-13Hemoglobin A1c/Hemoglobin.total in Blood7.3%Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for herHighS
2026-07-13Albumin/Creatinine [Mass Ratio] in Urine52mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2)HighS
2026-07-13Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-07-13Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.59-1.04 mg/dLNormalS
2026-07-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M67mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-07-13Accountable health communities (AHC) health-related social needs screening (HRSN) tool1{score}S

Physical Exam

Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]

SystemFinding
Consent and chaperoneBlood draw, urine sample and examination explained and agreed; female nurse present
GeneralWell; blood pressure 128/78, pulse 76; weight 90.9 kg
CardiovascularRegular rhythm; no ankle swelling
FeetInspected with her agreement: callus smaller after trimming; no ulcers

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later lifeactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes is documented only at the end of her life.
Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks; the old kidney injury is documented.
Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later lifeactiveconfirmed I12.9S — Synthetic modern diagnosis; hypertension is reported only at the end of her life.
Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contributeactiveconfirmed N18.2S — Synthetic kidney findings anchored to the documented permanent kidney damage.
Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention)activeconfirmed E11.22S — Synthetic modern coding.
Food insecurity: food runs out before the end of most monthsactiveconfirmed Z59.41S — Synthetic social need found on the screen.
Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrangeactiveconfirmed Z59.82S — Synthetic social need anchored to her rural Delta home.
Hyperlipidemia: LDL 146 mg/dLactiveconfirmed E78.5S — Synthetic laboratory finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationConsent and chaperone for every examination, test and procedureEvery visitCompleted todayEach step explained and agreed
ExaminationClinic blood pressure (seated, two readings, large cuff)Every visitCompleted today128/78
Self-managementHome blood pressure readingsSeven days to confirm the diagnosis; then twice a week, and daily for a week after any changeCompleted todayAverage 127/79
ExaminationWeight and BMIEvery visitCompleted today90.9 kg
LaboratoryHemoglobin A1cEvery 3 months until at goal, then every 6 monthsCompleted today7.3%, from 8.6%
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; 3 to 6 months after a treatment change; then every 6 months while moderately increasedCompleted today52 mg/g, from 96
LaboratoryPotassium, creatinine and eGFROne to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes)Completed todayPotassium 4.6 mmol/L; creatinine 1.02 mg/dL, eGFR 67
ExaminationFoot inspection, and comprehensive foot examinationInspection every visit; comprehensive examination yearlyCompleted todayInspection: callus smaller; no ulcers
Medication safetyMedicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and costEvery visitCompleted todayNo low blood sugar, dizziness, cough or genital itching; metformin increased
Self-managementDiabetes self-management education and supportAt diagnosis, then yearly and when needs changeCompleted todayClasses completed
SurveyDepression screen (PHQ-9)At intake, then every 6 to 12 monthsCompleted todayPHQ-9 3, asked privately
SurveySocial needs screen (AHC-HRSN) and resourcesAt intake, then every few months while needs are openCompleted todayOne core need positive (transportation on some days); food and utility needs met

Goal progress:

Guideline basis: Introduction and Methodology: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026); Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014); Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026); The Accountable Health Communities Health-Related Social Needs Screening Tool (2017); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Preventive visit in two months. Seven-month review in three months with the A1c, urine albumin, kidney function, the social needs screen and the autumn vaccines; rides booked. Next scheduled visit 2026-09-14: periodic adult preventive visit. [S]